These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

856 related items for PubMed ID: 33786754

  • 1. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daudén E, Conrad C, Mendes-Bastos P, Ferreira P, Leite L, Lu JD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas-Velasco M, Del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung J, Nogueira M, Chiricozzi A.
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [Abstract] [Full Text] [Related]

  • 2. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Rull EV, Llamas-Velasco M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A.
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [Abstract] [Full Text] [Related]

  • 3. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [Abstract] [Full Text] [Related]

  • 4. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [Abstract] [Full Text] [Related]

  • 5. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM, BADBIR Study Group.
    JAMA Dermatol; 2022 Oct 01; 158(10):1131-1141. PubMed ID: 35791876
    [Abstract] [Full Text] [Related]

  • 6. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J, Goldenberg G.
    Cutis; 2017 Feb 01; 99(2):123-127. PubMed ID: 28319618
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biologics for Psoriasis.
    Wride AM, Chen GF, Spaulding SL, Tkachenko E, Cohen JM.
    Dermatol Clin; 2024 Jul 01; 42(3):339-355. PubMed ID: 38796266
    [Abstract] [Full Text] [Related]

  • 9. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.
    J Immunol Res; 2019 Jul 01; 2019():2546161. PubMed ID: 31583255
    [Abstract] [Full Text] [Related]

  • 10. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
    Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A.
    Front Immunol; 2023 Jul 01; 14():1341708. PubMed ID: 38274801
    [Abstract] [Full Text] [Related]

  • 11. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
    Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, Borg E, Warren RB.
    PLoS One; 2019 Jul 01; 14(8):e0220868. PubMed ID: 31412060
    [Abstract] [Full Text] [Related]

  • 12. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL.
    J Manag Care Spec Pharm; 2018 Dec 01; 24(12):1210-1217. PubMed ID: 30479197
    [Abstract] [Full Text] [Related]

  • 13. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.
    Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA.
    Drugs; 2024 May 01; 84(5):565-578. PubMed ID: 38630365
    [Abstract] [Full Text] [Related]

  • 14. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2247-2259. PubMed ID: 28825875
    [Abstract] [Full Text] [Related]

  • 15. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
    Mastorino L, Dapavo P, Susca S, Cariti C, Siliquini N, Verrone A, Stroppiana E, Ortoncelli M, Quaglino P, Ribero S.
    J Dtsch Dermatol Ges; 2024 Jan 03; 22(1):34-42. PubMed ID: 37926830
    [Abstract] [Full Text] [Related]

  • 16. Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States.
    Zhdanava M, Fitzgerald T, Pilon D, Teneralli RE, Shah A, Diaz L, Lefebvre P, Feldman SR.
    J Dermatolog Treat; 2024 Dec 03; 35(1):2349658. PubMed ID: 38747375
    [Abstract] [Full Text] [Related]

  • 17. Safety of biologics in psoriasis.
    Kamata M, Tada Y.
    J Dermatol; 2018 Mar 03; 45(3):279-286. PubMed ID: 29226369
    [Abstract] [Full Text] [Related]

  • 18. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
    Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignahi F, Thyssen JP, Burge R, Mallbris L.
    J Eur Acad Dermatol Venereol; 2020 Jan 03; 34(1):39-46. PubMed ID: 31465593
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.
    Takeshima R, Kamata M, Suzuki S, Ito M, Watanabe A, Uchida H, Chijiwa C, Okada Y, Azuma S, Nagata M, Egawa S, Hiura A, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Tada Y.
    J Dermatol; 2024 Sep 03; 51(9):1216-1224. PubMed ID: 38804254
    [Abstract] [Full Text] [Related]

  • 20. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A.
    Curr Pharm Biotechnol; 2021 Sep 03; 22(1):7-31. PubMed ID: 32598253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.